Padcev

News

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

AZ cues up broader use of Imfinzi in bladder cancer

The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

News

NICE backs bladder cancer duo that can double survival

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.

News

Padcev/Keytruda extends survival in early bladder cancer

Astellas and Pfizer plan to file Padcev for earlier-stage bladder cancer after showing a survival benefit in a combination regimen with Keytruda.

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

AZ cues up broader use of Imfinzi in bladder cancer

Padcev/Keytruda scores again in early bladder cancer

EMA starts review of 'transformative' bladder cancer therapy

NICE backs bladder cancer duo that can double survival

Padcev/Keytruda extends survival in early bladder cancer

FDA clears Viridian's Tepezza rival for thyroid eye disease

Discover a new era of healthcare panel engagement: Grounded ...

Padcev

Editor's Picks